Get started
Author

Allicia Girvan

Observed institution: AbbVie (United States)
OpenAlex ID: A5029020558
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities
2023 · Joseph Mikhael, Allie Cichewicz, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
PDF
Real-World Treatment Patterns and Outcomes of Daratumumab Retreatment in Multiple Myeloma in the United States
2022 · Allicia Girvan, Junhua Yu, et al. · Blood · 5
Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥3 Lines of Therapy: A Real-World Evaluation in the United States
2022 · Allicia Girvan, Junhua Yu, et al. · Blood · 3
Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma
2024 · Sophia S. Li, Robert Schuldt, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States
2022 · Linda B. Baughn, Elizabeth S. Mearns, et al. · Blood · 1
Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis.
2025 · Robert Louis Coleman, Kayleen Ports, et al. · Journal of Clinical Oncology
PDF
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.
2024 · Sophia S. Li, Robert Schuldt, et al. · Journal of Clinical Oncology
Abstract A131: Clinical characteristics and outcomes of Black patients with multiple myeloma compared with other races
2023 · Shelli Spence, Junhua Yu, et al. · Cancer Epidemiology Biomarkers & Prevention
Real-World Progression-Free Survival and Treatment Patterns for t(11;14) Positive Patients with Multiple Myeloma with at Least 2 Prior Lines of Treatment
2023 · Allicia Girvan, Daniel Martins, et al. · Blood
P-233 Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma
2023 · Rahul Banerjee, Faiza Zafar, et al. · Clinical Lymphoma Myeloma & Leukemia
P-334 Fluorescence in situ hybridization (FISH) t(11;14) testing practices over time in patients with newly diagnosed multiple myeloma (MM) in the USA in the Flatiron Health database
2023 · Linda Baughn, Sophia Li, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-290 Physician Perspectives Regarding Conventional Marrow Testing and Measurable Residual Disease (MRD) Assessments to Guide Decision-Making in Myeloma
2023 · Rahul Banerjee, Faiza Zafar, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-348 Fluorescence in situ Hybridization (FISH) t(11;14) Testing Practices Over Time in Patients With Newly Diagnosed Multiple Myeloma (MM) in the USA in the Flatiron Health Database
2023 · Linda B. Baughn, Sophia Li, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-348 Fluorescence in situ Hybridization (FISH) t(11;14) Testing Practices Over Time in Patients With Newly Diagnosed Multiple Myeloma (MM) in the USA in the Flatiron Health Database
2023 · Linda B. Baughn, Sophia Li, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-290 Physician Perspectives Regarding Conventional Marrow Testing and Measurable Residual Disease (MRD) Assessments to Guide Decision-Making in Myeloma
2023 · Rahul Banerjee, Faiza Zafar, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
Clinician and Patient Perspectives on Treatment Decision-Making in Multiple Myeloma: A Qualitative Survey
2022 · Nina Shah, Elizabeth S. Mearns, et al. · Blood
Works count: 16
Citation count: 21
H-index: 3
I10-index: 1
Year
Topic
Type